

DCD liver transplantation: is donor age an issue?

O.Detry, H LeDinh, P Honoré, MF Hans, J Monard, MH
Delbouille, S Lauwick, JP Squifflet, A. Deroover, M.Meurisse


Dpt of Abdominal Surgery & Transplantation
CHU Liège, University of Liege, Belgium



16TH CONGRESS OF THE EUROPEAN
SOCIETY FOR ORGAN TRANSPLANTATION
PUSHING THE LIMITS



Conflict of Interest



DCD in liver transplantation

- Shortage of organ donors
- Waiting time and mortality on waiting lists
- DCD has been proposed to increase the pool
- Increased risk of PNF
- Increased risk of ischemic bile duct lesions (IBDL)
- Decreased graft and patient survival
- Increase risk of retransplantation

DCD in liver transplantation

- Donor age is an independant risk factor of graft failure after DBD liver transplantation
- Aged livers are more susceptible to ischemia/reperfusion injury
- Aged livers have less regenerative capacity
- Aged livers increase the risk of HCV recurrence

DCD in liver transplantation

DCD liver Tx and age

- Recommendations:
DCD donors > 45-50 years should not be used for liver transplantation

Durand, 2008, Liver Transpl

DCD LTx in Liège

- Program started in 2002 – all controlled DCD
- No particular selection compared to regular DBD donation
- Center oriented allocation, short cold ischemia
- Controlled DCD in OR with heparin & comfort therapy
- Low MELD score
 - HCC
 - Cirrhosis with encephalopathy and/or refractory ascitis
 - other (neurendocrine MTST)
- Aim: analyse our results according to donor's age

Methods

- Retrospective evaluation of a prospective database of 70 consecutive DCD LTx
- Comparison of 3 age groups:
 - < 56 y: n=32
 - 56-69 y: n=20
 - >69 y: n=18
- dWIT: from withdrawal to aortic perfusion
- Results: Median (IQR)
- Mean follow-up: 36 months

Donors' characteristics

	<56 y (n=32)	56-69 y (n=20)	>69 y (n=18)	<i>P</i>
Age (years)	44 (35.5-50.7)	62.5 (59-66.7)	73 (70-77)	<0.0001
DRI	1.8 (1.5-2.1)	2.3 (2.1-2.4)	2.6 (2.5-2.7)	<0.0001
Intensive care stay (days)	5 (4-8)	6.5 (5-8.7)	6.5 (3.7-9.2)	NS
Na (mmol/L)	145 (139-149)	143 (139-147)	141 (136-148)	NS
Total bilirubin (mg/dL)	0.38 (0.3-0.66)	0.3 (0.3-0.67)	0.44 (0.3-0.82)	NS
AST (UI/mL)	39.5 (24.7-59.7)	38 (23.5-69)	36 (26-69)	NS
GGT (UI/mL)	40 (27-118)	67 (39-118)	39 (24-92)	NS

Donors' characteristics

	<56 y (n=32)	56-69 y (n=20)	>69 y (n=18)	<i>P</i>
Age (years)	44 (35.5-50.7)	62.5 (59-66.7)	73 (70-77)	<0.0001
DRI	1.8 (1.5-2.1)	2.3 (2.1-2.4)	2.6 (2.5-2.7)	<0.0001
Intensive care stay (days)	5 (4-8)	6.5 (5-8.7)	6.5 (3.7-9.2)	NS
Na (mmol/L)	145 (139-149)	143 (139-147)	141 (136-148)	NS
Total bilirubin (mg/dL)	0.38 (0.3-0.66)	0.3 (0.3-0.67)	0.44 (0.3-0.82)	NS
AST (UI/mL)	39.5 (24.7-59.7)	38 (23.5-69)	36 (26-69)	NS
GGT (UI/mL)	40 (27-118)	67 (39-118)	39 (24-92)	NS

Procurement and Transplantation Characteristics

	<56 y (n=32)	56-69 y (n=20)	>69 y (n=18)	<i>P</i>
HTK/UW (n)	28/2	15/5	17/1	NS
DWIT (min)	20 (15-22)	21 (17-28)	19 (15.5-26.7)	NS
Withdrawal phase (min)	10 (7-12)	13 (8-19)	9 (5.7-17.2)	NS
Acirculatory phase (min)	9 (8-10)	8 (7.2-10.7)	9 (7-10.2)	NS
Hepatectomy time (min)	23 (20.7-30.7)	24.5 (17.2-30.7)	22.5 (18.2-23.5)	NS
CIT (min)	236 (212-287)	245 (204-323)	210 (187-270)	NS
Suture time (min)	41 (36-47)	42 (38-46)	39 (33-44)	NS

Procurement and Transplantation Characteristics

	<56 y (n=32)	56-69 y (n=20)	>69 y (n=18)	<i>P</i>
HTK/UW (n)	28/2	15/5	17/1	NS
DWIT (min)	20 (15-22)	21 (17-28)	19 (15.5-26.7)	NS
Withdrawal phase (min)	10 (7-12)	13 (8-19)	9 (5.7-17.2)	NS
Acirculatory phase (min)	9 (8-10)	8 (7.2-10.7)	9 (7-10.2)	NS
Hepatectomy time (min)	23 (20.7-30.7)	24.5 (17.2-30.7)	22.5 (18.2-23.5)	NS
CIT (min)	236 (212-287)	245 (204-323)	210 (187-270)	NS
Suture time (min)	41 (36-47)	42 (38-46)	39 (33-44)	NS

Recipients' characteristics

	<56 y (n=32)	56-69 y (n=20)	>69 y (n=18)	<i>P</i>
Age (years)	58 (51-63)	59.5 (50.7-64)	58.5 (51.7-64.2)	NS
Male (%)	90	81	83	NS
Liver disease (<i>n</i>)				
HCC	14	12	5	
Cirrhosis	14	8	13	
Other (CCK, NET, HAT)	4	0	0	
MELD	14.5 (11.2-17.7)	14 (10-18.5)	16 (14-24)	NS


Results

	<55y (n=32)	56-69y (n=20)	>69y (n=18)	<i>P</i>
Peak bilirubin (mg/dL)	2.7 (1.9-5.3)	3.1 (1.2-6.3)	4.5 (2.6-6.5)	NS
Peak AST (UI/mL)	1163 (715-2693)	1416 (587-2825)	1068 (699-3078)	NS
PNF (n)	0	0	0	
Retransplantation (n)	1 (HAT)	0	0	
Biliary complications				
fistula	0	1	2	
stenosis	2	2	1	
IBDL	0	0	0	

Graft and patient survivals

	<55y (n=32)	56-69y (n=20)	>69y (n=18)	<i>P</i>
Patient				NS
1 year	96%	95%	83%	
3 years	75%	74%	83%	
Graft				NS
1 year	93%	95%	83%	
3 years	73%	74%	83%	

Survival proportions: Survival of Three groups



Discussion

- Age > 55 y not a contra-indication for DCD donation
- Short WIT and CIT
- As CVA is more frequent in >55 year-old population, aged DCD donors might be a significant source of liver grafts

Liver Transplantation Using Controlled Donation After Cardiac Death Donors: An Analysis of a Large Single-Center Experience

Hani P. Grewal,¹ Darrin L. Willingham,¹ Justin Nguyen,¹ Winston R. Hewitt,¹ Bucin C. Taner,¹ Danielle Cornell,² Barry G. Rosser,¹ Andrew P. Keaveny,¹ Jamie Aranda-Michel,¹ Raj Satyanarayana,¹ Denise Harnois,¹ Rolland C. Dickson,¹ David J. Kramer,³ and Christopher B. Hughes¹

¹Department of Transplantation, Mayo Clinic, Jacksonville, FL; ²LifeQuest Organ Recovery Services, Gainesville, FL; and ³Department of Critical Care Medicine, Mayo Clinic, Jacksonville, FL

The use of donation after cardiac death (DCD) donors may provide a valuable source of organs for liver transplantation. Concerns regarding primary nonfunction (PNF) and intrahepatic biliary stricture (IHBSs) have limited the enthusiasm for their use. A retrospective analysis of 1436 consecutive deceased donor liver transplants performed between December 1998 and October 2006 was conducted. These included 108 DCD liver transplants, which were compared to 1328 transplants performed with organs from donors meeting the criteria for donation after brain death (DBD). The median follow-up was 48 months. The 1-, 3-, and 5-year patient survival and graft survival for DCD donors were 91.5%, 88.1%, and 88.1% and 79.3%, 74.5%, and 71.0%, respectively. The 1-, 3-, and 5-year patient survival and graft survival for DBD donors were 87.3%, 81.1%, and 77.2% and 81.6%, 74.7%, and 69.1%, respectively. Patient survival and graft survival were not significantly different between DCD donors less than 60 years old, DCD donors greater than 60 years old, and DBD donors. Causes of graft loss included IHBSs (n = 9), PNF (n = 4), recurrent hepatitis C virus (n = 4), hepatic artery thrombosis (n = 1), rejection (n = 2), and patient death (n = 13). Contrary to previously published data, excellent long-term patient survival and graft survival can be obtained with DCD allografts, and in our experience, they are equivalent to those obtained from DBD allografts. *Liver Transpl* 15: 1028-1035, 2009. © 2009 AASLD.




Figure 5. Graft survival versus the time after transplantation. Abbreviations: DBD, donation after brain death; DCD, donation after cardiac death; NS, not significant.

Thank you !

